Confronto
Cerebrolysin vs. Triptorelin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
96889-70-6
57773-63-4
Peso molecolare
nessun dato
1311.45 g/mol
Emivita
nessun dato
3 h
Sequenza
nessun dato
pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Meccanismo d'azione
Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight peptides (predominantly below 10 kDa) and free amino acids obtained by enzymatic cleavage of lipid-free porcine brain proteins. The manufacturer and preclinical literature describe a neurotrophic and neuroprotective mode of action said to mimic endogenous neurotrophic factors; cell and animal models have reported effects on neuronal survival, synaptogenesis and anti-apoptotic signalling (including PI3K/Akt). Because it is a complex, incompletely characterised mixture, the precise mechanism in humans remains unclear.
Triptorelin
Triptorelin binds with high affinity to the GnRH receptor in the pituitary. After initial stimulation of LH and FSH secretion (flare phase, about 1-2 weeks), receptor desensitisation follows with consecutive gonadotropin suppression. This results in a reversible chemical castration: in men testosterone, in women oestrogen suppression to the postmenopausal range.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
4
di cui sull'uomo
4
4
Effetti registrati
4
3
Contraddizioni aperte
1
0
Eventi avversi documentati
1
3
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Cerebrolysin and Triptorelin?
- Cerebrolysin is classified as "Ricerca (altro)", while Triptorelin is classified as "Ricerca (altro)". Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. Triptorelin: Synthetic decapeptide GnRH agonist with increased affinity over native gonadotropin-releasing hormone. FDA- and EMA-approved since the 1980s for prostate cancer, endometriosis and precocious puberty. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cerebrolysin or Triptorelin?
- The highest available evidence level is "RCT sull'uomo" for Cerebrolysin and "RCT sull'uomo" for Triptorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cerebrolysin and Triptorelin in Germany and the United States?
- Germania: Cerebrolysin — Non chiaro, Triptorelin — Su prescrizione. Stati Uniti: Cerebrolysin — Non approvato, Triptorelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.